Cargando…
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe ac...
Autores principales: | Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Kotloff, Karen, Frey, Sharon, Novak, Rick, Diemert, David, Spector, Stephen A., Rouphael, Nadine, Creech, C. Buddy, McGettigan, John, Khetan, Shishir, Segall, Nathan, Solis, Joel, Brosz, Adam, Fierro, Carlos, Schwartz, Howard, Neuzil, Kathleen, Corey, Larry, Gilbert, Peter, Janes, Holly, Follmann, Dean, Marovich, Mary, Mascola, John, Polakowski, Laura, Ledgerwood, Julie, Graham, Barney S., Bennett, Hamilton, Pajon, Rolando, Knightly, Conor, Leav, Brett, Deng, Weiping, Zhou, Honghong, Han, Shu, Ivarsson, Melanie, Miller, Jacqueline, Zaks, Tal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787219/ https://www.ncbi.nlm.nih.gov/pubmed/33378609 http://dx.doi.org/10.1056/NEJMoa2035389 |
Ejemplares similares
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021) -
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021) -
Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
por: Lin, Dan-Yu, et al.
Publicado: (2022) -
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022) -
1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
por: Follmann, Dean, et al.
Publicado: (2023)